Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

If the blood test - from California-based biotechnology company Freenome - was approved for market, it would be one of the ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

A common aromatic shrub that has served as traditional medicine for centuries could point the way toward innovative ...

Scientists from the University of Sharjah have found that a naturally growing aromatic plant contains ingredients with the ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

Researchers investigated the factors associated with treatment delay in patients with early-onset colorectal cancers.

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as colorectal cancer, in the five years.

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu ...